Novaliq’s CyclASol uses a new technology that allows cyclosporine to be soluble without water or preservatives.
Formulary Watch
Latest News
All News
Advertisement
A rise in the number of long COVID is sparking research efforts by the HHS, the CDC and drug companies to understand the conditions and develop treatments.
The updated PDUFA date is Feb. 28, 2023, and the planned advisory committee meeting is on hold pending review of NDA amendments.
The approval had been delayed as the regulatory agency reviewed data on Myfembree's impact on bone mineral density.
Susan Lang, CEO and founder of XIL Health, talks about the shifting trends and pressures that have led to a misalignment between the PBMs, their clients and consumers.
Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.
Confirmed cases of monkeypox in the United States have reached more than 7,500, according to the CDC.
Nubeqa, in combination with docetaxel, is now approved to treat metastatic prostate cancer.
The Inflation Reduction Act also allows Medicare to negotiate prices on some drugs and caps out-of-pocket costs for Medicare beneficiaries.
The tablet form has the same safety and efficacy as the capsule formulation and allows it to be administered with gastric-reducing therapies.
Advertisement
This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype. Its approval comes four months ahead of its PDUFA action date.
The committee will meet on Sept. 7, 2022, to discuss additional analyses of data from the Amylyx’s clinical studies. The updated PDUFA goal date is Sept. 29, 2022.
The FDA has requested Acadia conduct an additional trial of Nuplazid to support an indication in patients with Alzheimer’s disease.
Fresenius Kabi expects to receive FDA approval for its tocilizumab biosimilar in 2023 and is seeking approval in both intravenous and subcutaneous administration.
Results indicated the trial is unlikely to meet its primary endpoint, the change from baseline in the six-minute walk test at 24 weeks.
The new code, effective Oct. 1, 2022, allows APDS to be recognized as an distinct immunological disease.
This is the second trial in less than a month studying Keytruda that failed to meet endpoints.
OptumRx profiles four therapies that are expecting FDA decisions in the next few months.
Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022.
Investigators found that socioeconomic and financial barriers can affect patients’ access to oral cancer medications. They suggest that addressing these barriers could improve adherence.
Prime has removed six drugs from its formularies because generics are now available. One has been removed because it has been discontinued.
Stelara is the first biologic targeting both cytokines IL-12 and IL-23 and offers a therapeutic option for children six years of age and older living with active psoriatic arthritis, a rare disease.
Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store.
Zoryve, the first topical PDE4 inhibitor approved to treat patients with plaque psoriasis, will be available by mid-August.
The prescription drug launches include a therapy to treat adults with multiple myeloma and a treatment for overactive bladder. Dr. Reddy’s has also acquired several therapies from Eton Pharmaceuticals, including hypotension treatments.
The trial of the immunotherapy combination, although approved in other renal cell carcinoma indications, did not meet the endpoint of disease-free survival in patients with localized disease.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CMS sets the 2027 Part D bid amount at $296.05, will end premium subsidy program
2
PSG: Specialty drug spending predicted to increase 32% by 2028
3
Ashley Holzworth-Nash, Pharm.D., Evernorth
4
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
5